Medicaid Provider Spending

$1.09 trillion in Medicaid claims data, 2018–2024 · 617K+ providers

GENETOX, LLC

NPI: 1740731611 · MILWAUKEE, WI 53222 · Clinical Medical Laboratory · NPI assigned 10/17/2016

$6.46M
Total Medicaid Paid
79,526
Total Claims
48,358
Beneficiaries
4
Codes Billed
2018-01
First Month
2024-12
Last Month

Provider Details

Authorized OfficialKURTER, SELAHATTIN (OWNER)
NPI Enumeration Date10/17/2016

Related Entities

Other providers sharing the same authorized official: KURTER, SELAHATTIN

ProviderCityStateTotal Paid
WEST GROVE CLINIC, SC WAUWATOSA WI $3.77M
SPECTRUM HEALTHCARE, LLC MILWAUKEE WI $0.00

Monthly Spending Trend

Yearly Breakdown

YearClaimsTotal Paid
2018 10,352 $989K
2019 12,044 $1.12M
2020 12,664 $952K
2021 12,570 $980K
2022 10,981 $901K
2023 11,492 $801K
2024 9,423 $718K

Billing Codes

CodeDescriptionClaimsBeneficiariesTotal Paid
G0483 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed 38,983 23,608 $4.56M
80307 Drug test(s), presumptive, any number of drug classes; immunoassay 39,580 23,887 $1.82M
G0482 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed 563 507 $45K
G0481 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed 400 356 $31K